Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$18 Mln
Revenue (TTM)
$1 Mln
Net Profit (TTM)
$0 Mln
ROE
-2.2 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
3.5
Industry P/E
--
EV/EBITDA
-2.5
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-0.2
Face value
--
Shares outstanding
31,042,000
CFO
$-208.76 Mln
EBITDA
$-231.59 Mln
Net Profit
$-234.94 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Durect Corporation (DRRX)
| -27.5 | -25.6 | -31.9 | -55.8 | -48.4 | -53.4 | -31.6 |
|
BSE Sensex
| 4.4 | 2.7 | 8.5 | 10.1 | 14.6 | 21.7 | 11.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Durect Corporation (DRRX)
| 26.9 | -82.9 | -65.1 | -52.2 | -45.5 | 686.6 | -47.4 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Durect Corporation (DRRX)
|
0.5 | 18.3 | 0.5 | -4.9 | -2,246.9 | -140.2 | -- | 3.5 |
| 46.8 | 7,314.8 | 1,208.8 | 131.7 | 13.4 | 6.3 | 56.2 | 3.8 | |
| 136.7 | 6,715.6 | 4,022.6 | -31.6 | 3.7 | -1.1 | 618.4 | 2.1 | |
| 57.0 | 10,731.6 | 2,828.1 | -1,019.8 | -36.2 | -36.4 | -- | 4.5 | |
| 42.4 | 11,922.8 | 2,298.9 | 643.6 | 27.3 | 29.2 | 20 | 5.7 | |
| 54.5 | 6,645.3 | 1,084.3 | 485.4 | 57.0 | 103.8 | 14.3 | 13.7 | |
| 67.5 | 12,024.8 | 381.0 | -1,013.3 | -247.2 | -347.9 | -- | 125.8 | |
| 294.9 | 8,500.9 | 2,156.6 | 416.4 | 15.6 | 56.5 | 22.6 | 14.3 | |
| 26.3 | 9,977.9 | 3,159.0 | -3,357.0 | -76.7 | -30.5 | -- | 1.1 | |
| 120.2 | 11,931.3 | 2,412.6 | 305.8 | 20.5 | 11.6 | 40.9 | 4.8 |
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product candidate includes larsucosterol, an endogenous, orally bioavailable small molecule to play a regulatory role in... lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as for the treatment of patients with metabolic dysfunction-associated steatohepatitis. The company also offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; PERSERIS, an injectable suspension for the treatment of schizophrenia in adults; and Methydur to treat attention deficit hyperactivity disorder. It has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California. Address: 10240 Bubb Road, Cupertino, CA, United States, 95014-4166 Read more
Co-Founder, CEO, President & Director
Dr. James E. Brown D.V.M.
Co-Founder, CEO, President & Director
Dr. James E. Brown D.V.M.
Headquarters
Cupertino, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Durect Corporation (DRRX) stood at $ 24 Mln as on 31-Mar-25
The share price of Durect Corporation (DRRX) is $0.54 (NASDAQ) as of 23-May-2025 16:00 EDT. Durect Corporation (DRRX) has given a return of -48.43% in the last 3 years.
Durect Corporation (DRRX) has a market capitalisation of $ 18 Mln as on 22-May-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Durect Corporation (DRRX) is 3.54 times as on 22-May-2025, a 46% premium to its peers’ median range of 2.43 times.
Since, TTM earnings of Durect Corporation (DRRX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Durect Corporation (DRRX) and enter the required number of quantities and click on buy to purchase the shares of Durect Corporation (DRRX).
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product candidate includes larsucosterol, an endogenous, orally bioavailable small molecule to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as for the treatment of patients with metabolic dysfunction-associated steatohepatitis. The company also offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; PERSERIS, an injectable suspension for the treatment of schizophrenia in adults; and Methydur to treat attention deficit hyperactivity disorder. It has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California. Address: 10240 Bubb Road, Cupertino, CA, United States, 95014-4166
The CEO & director of Dr. James E. Brown D.V.M.. is Durect Corporation (DRRX), and CFO & Sr. VP is Dr. James E. Brown D.V.M..
There is no promoter pledging in Durect Corporation (DRRX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,202
|
|
|
1,193
|
|
|
1,192
|
|
|
1,073
|
|
|
998
|
|
|
850
|
|
|
731
|
|
|
665
|
|
|
663
|
| Durect Corporation (DRRX) | Ratios |
|---|---|
|
Return on equity(%)
|
-140.15
|
|
Operating margin(%)
|
-2246.86
|
|
Net Margin(%)
|
-935.81
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Durect Corporation (DRRX) was $0 Mln.
